Figure 6.

LC3B and p-EGFR significantly correlate with NANOG in human cervical neoplasia specimens. (A) Representative images of IHC staining of LC3B and p-EGFR in cervical tissue from normal, LGCIN, HGCIN, and cervical carcinoma patients. Scale bar: 25 µm. CIN, cervical intraepithelial neoplasia; LG-CIN, low-grade CIN; HG-CIN, high-grade CIN. (B) Correlation between each parameter. LC3B histoscore compared with NANOG and p-EGFR histoscores using a simple scatter plot. (C) Overall survival of cervical cancer patients was analyzed in Kaplan-Meier plots. Patients with high levels of LC3B and p-EGFR expression showed reduced overall survival (log-rank test, p = 0.003 and p = 0.004, respectively) compare with patients with low levels of LC3B and p-EGFR expression. Notably, patients with combined NANOG⁺ LC3B⁺, NANOG⁺ p-EGFR⁺, NANOG⁺ LC3B⁺ p-EGFR⁺ expression was showed significantly worse overall survival (log-rank test, p = 0.001, p = 0.002, and p = 0.005, respectively) than patients with NANOG⁻ LC3B⁻, NANOG⁻ p-EGFR⁻, NANOG⁻ LC3B⁻ p-EGFR⁻ expression. LC3B⁺, histoscore > 145; p-EGFR⁺, histoscore > 172. The p-values by Spearman correlation (R) (B) or Log-rank (Mantel-Cox) test (C) were indicated